^
BIOMARKER:

CD22 positive

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
1d
New P2 trial • Head-to-Head
|
TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
MLL rearrangement • KMT2A rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
3d
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
Enrollment closed
|
CD22 (CD22 Molecule)
|
CD22 positive
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Besponsa (inotuzumab ozogamicin) • daunorubicin • prednisone delayed-release tablet
13d
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Suspended, Stanford University | Enrolling by invitation --> Suspended
Trial suspension • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD22-CAR T-cell therapy
1m
Study of Sequential CAR-T Cell Treating Leukemia Children (clinicaltrials.gov)
P2, N=100, Recruiting, Beijing Boren Hospital | Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: May 2022 --> May 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression • CD22 positive
|
cyclophosphamide
1m
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov)
P2, N=100, Recruiting, Beijing Boren Hospital | Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: May 2022 --> May 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • Anti-CD22 CAR-T Cells
2ms
Trial initiation date
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 expression • CD22 positive
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • methotrexate • Besponsa (inotuzumab ozogamicin) • mercaptopurine • dexamethasone injection
2ms
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Nov 2021 --> Nov 2022
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
2ms
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Aug 2022 --> Aug 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
2ms
INOTUZUMAB OZOGAMICIN (INO) COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) – RESULTS FROM THE ITCC-059 1B TRIAL (SIOP 2022)
Background and AimsThe objective of this Phase I trial was to determine the recommended phase 2 dose (RP2D) of InO in combination with UKALL-R3 modified chemotherapy in pediatric BCP-ALL patients.MethodsMultiple relapsed or refractory CD22-positive BCP-ALL were enrolled. No toxic deaths related to InO were observed. Six out of the seven patients treated at 1.8 mg/m2 were responders (bone marrow M1 with or without hematological recovery) after cycle 1.ConclusionsThe RP2D of InO, in combination with vincristine and dexamethasone (10 mg/m2/day), was declared at 1.8 mg/m2/cycle.
Clinical
|
CD22 (CD22 Molecule)
|
CD22 positive
|
vincristine • Besponsa (inotuzumab ozogamicin)
3ms
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=18, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N=10 --> 18
Enrollment change • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
3ms
ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
These rare cases are easily confused with EBV positive diffuse large B-cell lymphoma, not otherwise specified (EBVDLBCL, NOS), cyclin D1 positive diffuse large B-cell lymphoma (cyclin D1DLBCL) and ALK positive anaplastic large cell lymphoma (ALKALCL), resulting in misdiagnosis. Being aware of these rare phenotypes is essential for pathologists to diagnose ALK+LBCL and guide appropriate treatment accurately.
Retrospective data • Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • CD38 (CD38 Molecule) • PAX5 (Paired Box 5) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD7 (CD7 Molecule) • IRF4 (Interferon regulatory factor 4) • SDC1 (Syndecan 1) • CD2 (CD2 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • SPN (Sialophorin)
|
ALK positive • ALK fusion • ALK translocation • CCND1 expression • MYC translocation • CD22 positive • SOX11 expression
4ms
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). (PubMed, Int J Hematol)
In conclusion, InO was well tolerated in children and promoted similar antileukemic efficacy as in adults. Nonetheless, the risk for VOD requires attention.
P1 data • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
4ms
ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (clinicaltrials.gov)
P1, N=36, Recruiting, University of Virginia | Trial completion date: Nov 2024 --> Aug 2028 | Trial primary completion date: Jan 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cytarabine • vincristine • prednisone • methotrexate • Besponsa (inotuzumab ozogamicin) • daunorubicin • Oncaspar liquid (pegaspargase) • Otrexup (methotrexate)
5ms
BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN (EHA 2022)
Eight patients were defined as NR and 10 patients as R. Patient disease characteristics in NR and R groups were homogeneous for age, sex, number of Philadelphia (Ph)-positive ALL patients, duration of 1 st remission, number of previous therapy lines including hematopoietic stem cell transplantation (HSCT) and Blinatumomab. HIPK2 downregulation needs to be further validated. CT and CP contributed equally
Clinical
|
GATA1 (GATA Binding Protein 1)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
5ms
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
5ms
LUNCHEON PRESENTATION: Discovery and optimization of CD22 VHH antibodies for CAR-T cell therapy (PEGS 2022)
We identified novel single domain antibodies (VHH) to CD22 for CAR-iNK immunotherapy in B-ALL and formatted as CARs, both in monovalent and tandem, bivalent formats. The combination of two VHHs in tandem, binding to both N- and C-terminal epitopes is most effective at eliminating CD22-positive tumor cells.
CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
5ms
VERY HIGH-RISK PRE-B ALL IN A 5-YEAR-OLD PATIENT WITH LYNCH SYNDROME: A CASE REPORT (ASPHO 2022)
She received chemotherapy with Fludarabine, Cytarabine and Idarubicin (IDA-FLAG), CD22 directed CAR-T therapy, and allogeneic bone marrow transplant. This is the youngest reported patient with Lynch syndrome and an aggressive, early-onset childhood cancer. Emerging evidence is linking heterozygous germline pathogenic variants in the mismatch repair genes with the development of childhood leukemia.
Clinical • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • CD19 (CD19 Molecule) • ETV6 (ETS Variant Transcription Factor 6) • MSH6 (MutS homolog 6) • CRLF2 (Cytokine Receptor Like Factor 2) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • KMT2A (Lysine Methyltransferase 2A) • PMS2 (PMS1 protein homolog 2) • CD22 (CD22 Molecule) • EPCAM (Epithelial cell adhesion molecule)
|
CRLF2 rearrangement • CD22 positive
|
cytarabine • idarubicin hydrochloride • fludarabine IV
5ms
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Enrolling by invitation, Stanford University | Recruiting --> Enrolling by invitation
Enrollment status • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD22-CAR T-cell therapy
6ms
New P2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 expression • CD22 positive
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • methotrexate • Besponsa (inotuzumab ozogamicin) • mercaptopurine • dexamethasone injection
7ms
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Recruiting --> Suspended
Trial suspension
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
YT-19/22
8ms
New P1 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV
8ms
New P1 trial
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • CD22 (CD22 Molecule) • IL15 (Interleukin 15)
|
CD22 positive
|
anti-CD19/CD22 CAR-T cells
8ms
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
8ms
Enrollment change • Trial withdrawal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
8ms
Enrollment closed
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
9ms
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. (PubMed, J Clin Oncol)
InO is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL. SOS after hematopoietic stem-cell transplantation and prolonged cytopenias were notable. CD22 modulation was identified as a mechanism of resistance. Expanded study of InO combined with chemotherapy is underway.
Clinical • P2 data • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
9ms
Haploidentical Donor-Derived CAR-T Cells Can be Safely and Effectively Co-Infused with the Haploidentical Graft, Depleted of Αβ T Cells: Report of Case Series (TCT-ASTCT-CIBMTR 2022)
Three patients had relapsed BCP-ALL after both haploidentical HSCT and autologous CD19 CAR-T cell, 3 after haploidentical HSCT, 2 after autologous CD19 CAR-T cell, 3 after intensive chemotherapy +/- blinatumomab n=2...Five 45% pts received treosulfan-based regimen, while TBI-based regimen was used in 6 55% pts. GvHD prophylaxis included tocilizumab and abatacept...The infusions did not compromise engraftment and GVHD control, while specific CAR-T toxicity was mild and manageable. We have documented allogeneic haploidentical CAR-T expansion and persistence.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Ovastat (treosulfan) • Actemra IV (tocilizumab) • Orencia (abatacept)
9ms
ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (clinicaltrials.gov)
P1, N=36, Recruiting, University of Virginia | Trial completion date: Nov 2025 --> Nov 2024 | Trial primary completion date: Jan 2022 --> Jan 2023
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cytarabine • vincristine • prednisone • methotrexate • Besponsa (inotuzumab ozogamicin) • daunorubicin • Oncaspar liquid (pegaspargase) • Otrexup (methotrexate)
10ms
Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain (ASH 2021)
Figure 1. Overall survival according to ALL status at inotuzumab start (A) and to duration of first complete remission (B)
Clinical
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
11ms
Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease (ASH 2021)
Prior to InO, blinatumomab was administered in n=14 and local irradiation in n=5 pts...Sinusoidal obstruction syndrome (SOS) was reported in 1 patient after transplant; conditioning in this patient consisted of treosulfan/fludarabine/thiotepa... This outcome analysis demonstrates that treatment with InO is an effective and promising approach in r/r-ALL patients with EM disease. However, allo-SCT alone seems not to be effective in maintaining disease control. Thus, autologous chimeric antigen receptor T-cells or advanced bi-specific antibodies as consolidation therapy should be evaluated in the future.
Clinical
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV • thiotepa • Ovastat (treosulfan)
11ms
Haploidentical Donor-Derived CAR-T Cells Are Safely and Effectively Co-Infused with the Haploidentical Graft, Depleted of Ab T Cells: Report of Case Series (ASH 2021)
Three patients had relapsed BCP-ALL after both haploidentical HSCT and autologous CD19 CAR-T cell, 3 after haploidentical HSCT, 2 after autologous CD19 CAR-T cell, 3 after intensive chemotherapy +/- blinatumomab (n=2)...Five (45%) pts received treosulfan-based myeloablative preparative regimen, while TBI-based regimen was used in 6 (55%) pts. GvHD prophylaxis included tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on day -1, +7, +14, +28...We have documented allogeneic haploidentical CAR-T expansion and persistence. Prospective testing of the approach is warranted.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CD34 (CD34 molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Ovastat (treosulfan) • Actemra IV (tocilizumab) • Orencia (abatacept)
11ms
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=1, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=28 --> 1 | Trial completion date: May 2023 --> May 2021 | Recruiting --> Terminated; Suitable patients were not recruited
Clinical • Enrollment change • Trial completion date • Trial termination
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD20 negative • CD22 positive
|
LB1909
11ms
Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
P1, N=26, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
12ms
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV
1year
TZR gene therapy for CD22-positive B-cell neoplasias (DGHO 2021)
Having demonstrated the efficacy and safety of the lead CD22 TCR candidate, we now will analyze efficiency in a xenograft model and on material of patients that relapsed after a CD19 CAR T cell therapy and of acute lymphoblastic leukemia (ALL) -relapsed children after treatment with the CD22 targeting agent inotuzumab. Patients that have relapsed from CD19 or CD22 CAR therapy might be rescued by the treatment with CD22 TCR T cells. We here demonstrate the development of a CD22 candidate TCR for further preclinical development and translation into early clinical trials in patients with CD22-positive B cell malignanices.
IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
P1, N=26, Not yet recruiting, Dana-Farber Cancer Institute
New P1 trial • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
1year
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. (PubMed, Leuk Lymphoma)
This drug combination is not possible within a therapeutically useful range of doses due to toxicities. Antitumor activity was observed in heavily pretreated patients (ClinicalTrials.gov, Identifier NCT01535989).
Clinical • P1 data • Journal • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Torisel (temsirolimus) • Besponsa (inotuzumab ozogamicin)
1year
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Active, not recruiting --> Recruiting | Initiation date: Jan 2021 --> May 2021
Clinical • Enrollment open • Trial initiation date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 expression • CD22 positive
1year
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Nov 2021
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients (clinicaltrials.gov)
P4, N=102, Recruiting, Pfizer | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Nov 2022
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1b/2, N=42, Recruiting, Roswell Park Cancer Institute | Trial completion date: Feb 2023 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2023
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
over1year
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
P1, N=12, Recruiting, Hebei Yanda Ludaopei Hospital | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
YT-19/22